Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. - Wikidata - awgldk - TriplyDB

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

http://www.wikidata.org/entity/Q36950805

about

The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma Smoldering multiple myeloma: present position and potential promises.Identification of the potential risk factors for monoclonal gammopathy of undetermined significance of progression.Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma Novel Immunotherapies for Multiple Myeloma.Performance Evaluation of Serum Free Light Chain Analysis: Nephelometry vs Turbidimetry, Monoclonal vs Polyclonal Reagents.Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma.Comparison of Fully Automated and Semiautomated Systems for Protein Immunofixation Electrophoresis.Active multiple myeloma suppresses and typically eliminates coexisting MGUS.Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma.Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.Prognostic value of serum heavy/light chain ratios in patients with POEMS syndrome.Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio The Effect of Suppressed Levels of Uninvolved Immunoglobulins on the Prognosis of Symptomatic Multiple Myeloma.Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases.IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.Involved/uninvolved immunoglobulin ratio identifies monoclonal gammopathy of undetermined significance patients at high risk of progression to multiple myeloma.Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.Evolutionary biology of high-risk multiple myeloma.The clinical utility of serum free light chain and heavy/light chain assays in monitoring disease activity in patients with IgG myeloma after achieving a deep response.Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.Serum Free Light Chain Assay and κ/λ Ratio Performance in Patients Without Monoclonal Gammopathies: High False-Positive Rate.Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials

P2860

Q33695919-6FBAAF38-93B8-4F80-85E9-D8E42DE5070C Q34292995-ED77F430-293B-41E8-A2EC-BBDA91B045C7 Q34316559-2098BF7C-8FE8-46BC-A38D-654766E91F25 Q34525834-99B6CF71-50B6-407B-93F5-60763D6D752E Q35132283-B67342D1-3F56-4958-B9CA-3C1694FC3731 Q35847877-134F53DF-6438-4309-82BF-E5C198BCEA76 Q36799760-4D59F066-4781-4D20-86B2-8FA37E8D36BB Q37171994-AD374C61-0DF1-46AC-A05F-EC1EB47AB413 Q38151230-BD863637-4EDF-43ED-AD33-40B98E39F61A Q38199534-46FF81EC-5186-4482-BAAC-CAC04F5EB028 Q38219408-05624CA2-CFD3-4434-8B47-A3C39C2B6376 Q38640444-87B27FA9-4F60-427B-8601-EA6D1353904E Q38675621-6ADC2450-BFF9-4B42-97CF-1D14A2DA8D76 Q38722312-E54464E0-8027-4F20-A379-ED951BDA97A5 Q39594256-53F596C8-C3D3-4A7A-BEFD-B1E68A17FD9D Q40114748-636AFB4E-A51E-4556-A803-53B39AB45ADE Q40455903-E499EAE5-EF8E-4B40-9FF5-E443B474F562 Q41245046-AE1AB7F5-132A-42F9-9CC2-5CE35651B6D7 Q41348558-F8453DD5-5457-4592-BD4A-0C1D42F764D0 Q41896714-C744B30E-2BA7-4B70-A857-8F4840EE5479 Q42250752-6CC3981C-8A3A-41B6-A9F0-65846C2637B3 Q42356395-71AA2765-ADB5-4BEE-ACDF-19633AFDA118 Q44818652-F3975A24-25ED-48BF-B76C-1DA927A8D69C Q46440869-069C25A5-A721-454A-9FA6-E87F675ED3DE Q46878801-6541CE69-F173-4D6A-8111-9842F553D5A2 Q46990391-081A5964-3276-4EA3-8EC2-4C4CEEDEB5C8 Q47102955-01CC74EF-DAF4-4AE9-84C6-94B80FF02E00 Q47642719-C382EA88-B4F1-472B-957C-B786392464B3 Q47679443-2A2BCCD8-F0BA-4E3B-8DF4-3BBF84AC2984 Q47833870-7EEF418D-5FE5-43DD-A1DE-0CED1758347D Q47913337-9877B78B-CBED-48A6-B290-CD052C13EA54 Q48154938-962AE3B9-0A2E-447D-AA9B-AD7D37BBD0F8 Q50000214-EFB55694-F95F-450A-B84A-C32FABA2DA82 Q50589659-261D178E-A9CB-42EC-A6D4-961B3AE9A1C7 Q51606154-89C50BAE-85ED-4307-A3A6-6935FE642A62 Q53093363-AEBD9730-BE05-4A91-8A5C-02C4B0BB6554 Q58760132-0359506D-1A7A-4AA8-8FEC-A7B0A74C9972

P2860

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

http://www.wikidata.org/entity/Q36950805

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Suppression of uninvolved immu ...... actor for progression of MGUS.

@en

type

label

Suppression of uninvolved immu ...... actor for progression of MGUS.

@en

prefLabel

Suppression of uninvolved immu ...... actor for progression of MGUS.

@en

P1433

Q36950805-EAFF185C-6B6D-4B4A-97E0-6415E7CEB5DD

P1476

Q36950805-9BC42DA2-7D16-4E8F-A009-20F799F9F7B8

P2093

Q36950805-08AD80B7-9ADD-46F2-A748-AB1B934F3720

Q36950805-1A3E3989-01ED-4435-86A0-AB99CF136FA6

Q36950805-382F9711-9F6B-4F42-A495-8DE1C58A5F08

Q36950805-40EFC696-9275-4ACC-9F22-5445BF0DFD58

Q36950805-452FFEFB-6142-4DFD-85AA-6D2CFDF11768

Q36950805-A9E41911-A0BD-4C0B-9323-809D49F5E998

Q36950805-B7162F00-BFB3-4340-9BB8-40F8BB754372

Q36950805-BB003A16-2F01-4BDF-9B3A-FA5B23AFF191

Q36950805-EA39AE30-A50F-4E4F-94E2-A77207144B68

Q36950805-F7778D31-5454-4E2C-91C2-B6095A1BC668

P2860

Q36950805-0006B6A7-D46A-4EAD-9210-55D48CC716CE

Q36950805-11459E9B-1692-4498-B31E-94EE31E5AC82

Q36950805-4600E5EE-9775-49E0-8DE3-08E9C3AA6CE2

Q36950805-5068F6AB-E8F4-4309-A9D0-27AF654F1DB9

Q36950805-5830334C-C0DF-4856-AF67-ED208F703668

Q36950805-6F7A27B5-B299-4438-BA8F-7FF5422F3653

Q36950805-74D27746-AC5C-4068-9F24-42298966A43E

Q36950805-7A1E16E9-1223-4627-AC63-721350071D7E

Q36950805-83771841-4232-4E81-8CD5-01B9F4517347

Q36950805-A01DD6F9-5DB9-49DD-ACBC-3D9272C79041

P2888

Q36950805-B43DEBAE-17B0-4C60-B515-A9C5BED4DA28

P304

Q36950805-5BBEAFC8-DA6E-4C0B-A364-242178FD838D

P31

Q36950805-C4587A19-CAF0-43A3-BE9A-4DD12C5EB1C1

P356

Q36950805-577F94CA-6D7A-4817-8C0B-53C30433EB93

P433

Q36950805-9DA378DB-D9DC-4E7C-AFFB-F5BF5EC5E24C

P478

Q36950805-ADB6B52E-693B-49D0-B1CB-14048E64155B

P50

Q36950805-00B51F2C-085D-4486-9A22-C7CAA68F84BF

Q36950805-013A6C81-7752-443D-8859-0E2C46193862

Q36950805-31942E06-04EF-4421-9F00-2159AF2678FC

Q36950805-59784E28-7C6B-4F93-98C9-842CC11FAB63

P577

Q36950805-5408F6EE-DF40-4AFC-95C2-B55861A3D27B

P698

Q36950805-3FAAEFC0-2FC1-4E02-9920-5B4C1843D059

P921

Q36950805-C47979D9-B034-480E-A89F-B963D9C854DB

P932

Q36950805-427550A7-9878-4257-9312-85A0AD677400

P356

P1433

P1476

Suppression of uninvolved immu ...... factor for progression of MGUS

@en

P2093

C L Colby

http://www.w3.org/2001/XMLSchema#string

D R Larson

http://www.w3.org/2001/XMLSchema#string

J A Katzmann

http://www.w3.org/2001/XMLSchema#string

J T Benson

http://www.w3.org/2001/XMLSchema#string

L J Melton

http://www.w3.org/2001/XMLSchema#string

O Landgren

http://www.w3.org/2001/XMLSchema#string

R A Kyle

http://www.w3.org/2001/XMLSchema#string

R Clark

http://www.w3.org/2001/XMLSchema#string

S Kumar

http://www.w3.org/2001/XMLSchema#string

T M Therneau

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.

Prevalence of monoclonal gammopathy of undetermined significance.

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

A monoclonal gammopathy precedes multiple myeloma in most patients

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

P2888

P304

208-212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2012.189

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

Arthur R Bradwell

S. Vincent Rajkumar

P577

2012-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22781594

http://www.w3.org/2001/XMLSchema#string

P921

P932

3691011

http://www.w3.org/2001/XMLSchema#string